In our Early Stage Islet we engage in high-risk, early-stage investments, diversifying our portfolio to mitigate risks associated with binary outcomes.
Developing Antibody Technologies.
Advancing radiotherapeutics to treat solid tumors.
Advancing Cancer Detection.
Provider of Evidence Based Care Systems.
Personlised Cancer Theraphy that boosts tumour-specific responses of the immune system.
Ultrasensitive cancer diagnostics & monitoring.
Precision Nanomedicine for Improved Diagnosis and Treatment.